- Home
- DD vs RMD Comparison
DD vs RMD Comparison
Compare DD & RMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DD
- RMD
- Stock Information
- Founded
- DD 2015
- RMD 1989
- Country
- DD United States
- RMD United States
- Employees
- DD N/A
- RMD N/A
- Industry
- DD Major Chemicals
- RMD Medical/Dental Instruments
- Sector
- DD Industrials
- RMD Health Care
- Exchange
- DD Nasdaq
- RMD Nasdaq
- Market Cap
- DD 29.9B
- RMD 36.7B
- IPO Year
- DD N/A
- RMD 1995
- Fundamental
- Price
- DD $75.66
- RMD $254.41
- Analyst Decision
- DD Buy
- RMD Buy
- Analyst Count
- DD 13
- RMD 12
- Target Price
- DD $85.31
- RMD $259.40
- AVG Volume (30 Days)
- DD 2.4M
- RMD 748.6K
- Earning Date
- DD 07-30-2025
- RMD 07-31-2025
- Dividend Yield
- DD 2.17%
- RMD 0.82%
- EPS Growth
- DD N/A
- RMD 37.08
- EPS
- DD N/A
- RMD 8.91
- Revenue
- DD $12,521,000,000.00
- RMD $5,021,529,000.00
- Revenue This Year
- DD $6.20
- RMD $10.37
- Revenue Next Year
- DD $4.25
- RMD $7.77
- P/E Ratio
- DD N/A
- RMD $28.96
- Revenue Growth
- DD 4.51
- RMD 9.54
- 52 Week Low
- DD $53.77
- RMD $195.00
- 52 Week High
- DD $90.06
- RMD $263.05
- Technical
- Relative Strength Index (RSI)
- DD 69.08
- RMD 52.85
- Support Level
- DD $72.89
- RMD $251.40
- Resistance Level
- DD $76.78
- RMD $261.08
- Average True Range (ATR)
- DD 1.56
- RMD 4.21
- MACD
- DD 0.71
- RMD -0.51
- Stochastic Oscillator
- DD 89.58
- RMD 34.28
About DD DuPont de Nemours Inc.
DuPont is a diversified global specialty chemicals company created in 2019 as a result of the DowDuPont merger and subsequent separations. Its portfolio includes specialty chemicals and downstream products that serve the electronics, water, construction, safety and protection, automotive, and healthcare industries. DuPont plans to spin off its electronics business by the end of 2025, which will be named Qnity.
About RMD ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.